专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20100028921A1 RISK STRATIFICATION FOR ACUTE CORONARY SYNDROME BY MEANS OF FRAGMENTS/PARTIAL PEPTIDES OF PROVASOPRESSIN, ESPECIALLY COPEPTIN OR NEUROPHYSIN II 有权
标题翻译：急性冠状动脉综合征的风险分析方法是通过片段/部分抗原肽，特异性COPEPTIN或神经营养蛋白II
公开(公告)号：US20100028921A1
公开(公告)日：2010-02-04
申请号：US12447105
申请日：2007-10-26
申请人： Andreas Bergmann , Nils Morgenthaler , Jana Papassotiriou , Joachim Struck , Leong L. Ng
发明人： Andreas Bergmann , Nils Morgenthaler , Jana Papassotiriou , Joachim Struck , Leong L. Ng
IPC分类号： C12Q1/48 , G01N33/68 , C12Q1/28
CPC分类号： G01N33/68 , G01N33/6893 , G01N33/74 , G01N2333/47 , G01N2410/04 , G01N2800/324 , G01N2800/50
摘要： The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.
摘要翻译：本发明涉及用于急性冠状动脉综合征（ACS），特别是急性心肌梗塞（AMI）和心绞痛（AP）的风险分层的方法，其中促增生素（proAVP）或其片段和部分肽，特别是共肽蛋白或神经生物素II ，由体外诊断确定。

12. 发明申请

US20080213746A1 Methods of Diagnosis and Risk Stratification of Adverse Events in Post Myocardial Infarction Patients Using Pro-adrenomedullin 有权
标题翻译：使用前肾上腺髓质素的心肌梗死后患者不良事件的诊断和风险分层方法
公开(公告)号：US20080213746A1
公开(公告)日：2008-09-04
申请号：US11937061
申请日：2007-11-08
申请人： Leong Loke Ng , Andreas Bergmann , Joachim Struck , Nils Morgenthaler , Jana Papassotiriou
发明人： Leong Loke Ng , Andreas Bergmann , Joachim Struck , Nils Morgenthaler , Jana Papassotiriou
IPC分类号： G01N33/53
CPC分类号： G01N33/74 , G01N33/6893 , G01N2800/324 , G01N2800/50
摘要： The invention provides methods for the diagnosis and risk stratification of adverse events in post-myocardial infarction patients by means of proADM, whereby a determination of the marker pro-adrenomedullin or partial sequence or a fragment thereof or contained in a marker combination (panel, cluster) is carried out on a post-myocardial infarction patient. The invention also provides a diagnostic device and a kit for the performance of the method of the method of the invention.
摘要翻译：本发明提供了通过proADM诊断和危及心肌梗塞后不良事件分层的方法，由此确定标记物前肾上腺髓质素或其部分序列或其片段或包含在标记物组合中（面板，簇）在心肌梗死后患者中进行。本发明还提供了用于执行本发明方法的诊断装置和试剂盒。

13. 发明授权

US07413850B2 Uses of carbamoyl phosphate synthetase for the diagnois of inflammatory diseases and sepsis 有权
标题翻译：氨基甲酰磷酸合成酶用于诊断炎性疾病和败血症
公开(公告)号：US07413850B2
公开(公告)日：2008-08-19
申请号：US10511756
申请日：2003-04-15
申请人： Andreas Bergmann , Joachim Struck , Monika Uhlein
发明人： Andreas Bergmann , Joachim Struck , Monika Uhlein
IPC分类号： C12Q1/00 , G01N33/53 , G01N33/563 , C12P21/06 , A61K49/00 , A61K33/43
CPC分类号： G01N33/6893 , C12Q1/34 , C12Q1/48 , G01N2333/9015 , G01N2800/26
摘要： Use of carbamoyl phosphate synthetase 1 (CPS 1) and/or of fragments of the N-terminal part of CPS 1 from body fluids or body tissues as marker peptides for the diagnosis and for the prognosis and the monitoring of inflammations and infections, including sepsis, and of liver failure as part of multiorgan failure or for determinations in connection with inflammatory and other liver diseases.
摘要翻译：使用氨基甲酰磷酸合成酶1（CPS 1）和/或CPS 1的N末端部分片段从体液或身体组织中作为标志物肽用于诊断和预后以及监测炎症和感染，包括败血症，以及作为多器官衰竭或与炎性和其他肝脏疾病有关的确定的一部分的肝衰竭。

14. 发明授权

US07132246B2 Use of soluble cytokeratin-1-fragments in diagnostics and therapy 有权
标题翻译：在诊断和治疗中使用可溶性细胞角蛋白-1-片段
公开(公告)号：US07132246B2
公开(公告)日：2006-11-07
申请号：US10480848
申请日：2002-06-12
申请人： Andreas Bergmann , Joachim Struck , Monika Ühlein
发明人： Andreas Bergmann , Joachim Struck , Monika Ühlein
IPC分类号： G01N33/53
CPC分类号： C07K14/4741 , G01N33/6893 , G01N2333/4742 , G01N2800/26
摘要： Use of novel soluble cytokeratin 1 fragments from body fluids or body tissues as marker peptides for the diagnosis, prognosis and monitoring of the course of inflammations and infections and/or as a target for the therapeutic influencing of the course of inflammations and/or infections.
摘要翻译：使用来自体液或身体组织的新型可溶性细胞角蛋白1片段作为标记肽，用于诊断，预后和监测炎症和感染过程，和/或用作治疗性影响炎症和/或感染过程的靶标。

15. 发明申请

US20060029990A1 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity 失效
标题翻译：通过测定lasp-1免疫反应性来诊断炎性疾病和感染的方法
公开(公告)号：US20060029990A1
公开(公告)日：2006-02-09
申请号：US10511758
申请日：2003-04-15
申请人： Andreas Bergmann , Christina Fischer-Schulz , Joachim Struck
发明人： Andreas Bergmann , Christina Fischer-Schulz , Joachim Struck
IPC分类号： G01N33/53 , G01N33/537 , G01N33/543
CPC分类号： G01N33/566 , G01N33/6893 , G01N33/6896 , G01N2800/26
摘要： Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.
摘要翻译：用于早期诊断和诊断的方法，用于预测和评估炎性疾病和感染，特别是脓毒症样全身感染和阿尔茨海默氏病的严重性和治疗伴随监测，其中蛋白质LASP- 1（SEQ ID NO：1）或蛋白质LAP-1（SEQ ID NO：16）或这些蛋白质之一的游离和/或蛋白结合形式的免疫反应性片段优选作为免疫反应性生物流体或任选的组织样品，并且根据存在和/或数量的炎症性疾病或感染的治疗的存在，预期进程，严重程度或成功性得出结论的蛋白质。

16. 发明授权

US09046532B2 Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin 有权
标题翻译：通过确定降钙素原的水平，对患有原发性非传染性疾病的患者进行抗生素治疗的风险评估
公开(公告)号：US09046532B2
公开(公告)日：2015-06-02
申请号：US13264252
申请日：2010-04-14
申请人： Andreas Bergmann , Joachim Struck
发明人： Andreas Bergmann , Joachim Struck
IPC分类号： G01N33/00 , G01N33/74
CPC分类号： G01N33/74 , G01N2333/585 , G01N2800/32 , G01N2800/325
摘要： A diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic, as well as a kit for performing the method and methods of treatment based thereon.
摘要翻译：用于鉴定患有可能通过向所述受试者施用抗生素诱导的不利结果的风险增加的主要非传染性疾病的受试者的诊断方法，包括测定降钙素原（PCT）水平或片段或其在来自所述受试者的体液样品中具有至少12个氨基酸残基的长度的前体或片段以及所确定的水平与通过施用抗生素诱导的潜在风险的相关性，以及用于执行基于其的处理方法和方法的试剂盒。

17. 发明授权

US08906857B2 Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists 有权
标题翻译：内皮素，内皮素激动剂和肾上腺髓质素拮抗剂危重病人诊断和治疗方法
公开(公告)号：US08906857B2
公开(公告)日：2014-12-09
申请号：US12364911
申请日：2009-02-03
申请人： Andreas Bergmann , Joachim Struck , Nils G. Morgenthaler
发明人： Andreas Bergmann , Joachim Struck , Nils G. Morgenthaler
IPC分类号： A61K39/395 , G01N33/53 , A61K38/17 , G01N33/74 , C07K16/22 , C07K16/26
CPC分类号： C07K16/22 , C07K16/26 , G01N33/74 , G01N2333/575 , G01N2333/5754 , G01N2800/60
摘要： The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used as for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.
摘要翻译：使用重症患者体液中前肾上腺髓质素（pro-adrenomedullin（pro-ADM）/ pro-endothelin（pro-end））免疫反应性的比例用于诊断，病程控制和预后，包括对死亡风险的评估，严重威胁生命的疾病。此外，提供了治疗具有高水平的pro-ADM但具有包含血管收缩性内皮素或其前体的药物和/或内皮素激动剂或肾上腺髓质素拮抗剂的前-THT免疫反应性水平不足的危重患者。

18. 发明授权

US08450463B2 Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method 有权
标题翻译：用于确定用于医学诊断目的的内皮素形成的方法，以及用于进行这种方法的抗体和试剂盒
公开(公告)号：US08450463B2
公开(公告)日：2013-05-28
申请号：US13398211
申请日：2012-02-16
申请人： Andreas Bergmann , Joachim Struck
发明人： Andreas Bergmann , Joachim Struck
IPC分类号： C07K16/00
CPC分类号： C07K16/00 , G01N33/57488 , G01N33/6893 , G01N33/74 , G01N2333/5754 , Y10S435/975
摘要： Described herein is an in vitro method for the determination of the formation of endothelins in serious diseases, in particular cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient, in which relatively long-lived peptide fragments of the processed primary prepro- or proendothelins are determined which contain neither the actual biologically active endothelin nor its direct precursor big endothelin. In particular, disclosed are antibodies and kits for selectively detecting these fragments.
摘要翻译：本文描述的是用于测定人类患者的全血，血浆或血清中严重疾病，特别是心血管疾病，炎症，败血症和癌症中内皮素形成的体外方法，其中相对长寿的肽片段的被处理的原始前原或前内皮素被确定为既不含实际的生物活性内皮素也不包含其直接前体大内皮素。特别地，公开了用于选择性检测这些片段的抗体和试剂盒。

19. 发明授权

US08436135B2 Diagnosis and risk stratification by determining the marker CT-proADM 有权
标题翻译：通过确定标记CT-proADM进行诊断和危险分层
公开(公告)号：US08436135B2
公开(公告)日：2013-05-07
申请号：US12520159
申请日：2007-12-20
申请人： Andreas Bergmann , Joachim Struck
发明人： Andreas Bergmann , Joachim Struck
IPC分类号： A61K38/00
CPC分类号： G01N33/6884 , C07K14/47 , C07K14/575 , C07K16/26 , G01N33/6893 , G01N33/74 , G01N2333/47 , G01N2800/12 , G01N2800/32
摘要： The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No, 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method.
摘要翻译：本发明涉及用于诊断和/或分层疾病风险的新型诊断标记物CT-proADM（preproADM的C末端片段，SEQ ID NO：1）。还公开了用于诊断和/或分层疾病，特别是心血管疾病，心脏功能不全以及肺和呼吸道的感染和/或炎症的风险的方法。在所述方法中，在待检查的患者中确定CT-proADM（SEQ ID No.1）标记或其片段的部分肽或包含在标记组合（面板，群集）中的所述标记。本发明还涉及诊断装置以及用于执行所述方法的套件。

20. 发明授权

US08354506B2 Antibodies for the selective determination of procalcitonin 1-116 有权
标题翻译：用于选择性测定降钙素原的抗体1-116
公开(公告)号：US08354506B2
公开(公告)日：2013-01-15
申请号：US12529089
申请日：2008-02-21
申请人： Andreas Bergmann , Joachim Struck
发明人： Andreas Bergmann , Joachim Struck
IPC分类号： C07K16/26
CPC分类号： G01N33/6854 , C07K16/26 , C07K2317/34 , G01N33/74 , G01N2333/585
摘要： The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient for diagnostic purposes, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of procalcitonin, or procalcitonin partial peptides derived therefrom, having the amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116 (SEQ ID NO: 1.) Also disclosed are antibodies and kits for carrying out such a method.
摘要翻译：本发明提供了用于诊断目的的用于确定患者生物样品中的降钙素原和降钙素原衍生物的免疫诊断方法，特别是在监测和控制治疗以及监测局部或全身细菌感染，炎症，败血症或神经变性疾病。特别地，该方法检测在完全降钙素原1-116（SEQ ID NO：1）的氨基末端位置1和2中具有氨基酸丙氨酸和脯氨酸（Ala-Pro，AP）的降钙素原或降钙素原部分肽的分子形式 ID NO：1）还公开了用于进行这种方法的抗体和试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式